'On consolidated basis

Quarter ended June 2025 compared with Quarter ended June 2024.

Net sales (including other operating income) of Torrent Pharmaceuticals has increased 11.16% to Rs 3178 crore.  Operating profit margin has jumped from 31.62% to 32.47%, leading to 14.16% rise in operating profit to Rs 1,032.00 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 14.23% to 12.62%.   Purchase of finished goods cost fell from 10.83% to 10.77%.   Employee cost increased from 19.04% to 19.28%.   Other expenses fell from 24.61% to 24.44%.   

PBIDT rose 7.22% to Rs 995 crore.  Provision for interest fell 25.33% to Rs 56 crore.  

PBDT rose 10.08% to Rs 939 crore.  Provision for depreciation rose 2.03% to Rs 201 crore.  

Profit before tax grew 12.50% to Rs 738.00 crore.  Share of profit/loss were nil in ...

• 

  (13-Jan-2026)

  HCL Technologies

  Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
• 

  (13-Jan-2026)

  Tata Consultancy Services

  Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
• 

  (12-Jan-2026)

  Krishana Phoschem

  Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
• 

  (11-Jan-2026)

  Avenue Supermarts

  Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026